APG Asset Management N.V. Raises Stake in Edwards Lifesciences Co. (NYSE:EW)

APG Asset Management N.V. increased its stake in Edwards Lifesciences Co. (NYSE:EW - Free Report) by 261.1% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 424,027 shares of the medical research company's stock after purchasing an additional 306,596 shares during the quarter. APG Asset Management N.V. owned approximately 0.07% of Edwards Lifesciences worth $30,315,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in EW. Crowley Wealth Management Inc. purchased a new position in shares of Edwards Lifesciences during the fourth quarter valued at about $26,000. Millstone Evans Group LLC purchased a new stake in Edwards Lifesciences in the fourth quarter worth $29,000. Migdal Insurance & Financial Holdings Ltd. bought a new stake in Edwards Lifesciences during the 4th quarter valued at about $30,000. Roble Belko & Company Inc purchased a new stake in shares of Edwards Lifesciences in the fourth quarter valued at approximately $46,000. Finally, Catalyst Capital Advisors LLC bought a new position in shares of Edwards Lifesciences during the 4th quarter worth $54,000. 79.46% of the stock is owned by hedge funds and other institutional investors.

Edwards Lifesciences Stock Performance

Shares of Edwards Lifesciences stock traded up $0.40 during trading on Monday, reaching $69.80. The company's stock had a trading volume of 843,703 shares, compared to its average volume of 4,644,578. Edwards Lifesciences Co. has a fifty-two week low of $58.93 and a fifty-two week high of $95.25. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. The firm has a market cap of $41.03 billion, a PE ratio of 10.01, a P/E/G ratio of 4.82 and a beta of 1.15. The company has a 50-day moving average price of $71.32 and a two-hundred day moving average price of $70.74.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its quarterly earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. On average, analysts forecast that Edwards Lifesciences Co. will post 2.45 EPS for the current year.

Wall Street Analyst Weigh In

EW has been the subject of a number of recent research reports. Truist Financial reduced their price objective on shares of Edwards Lifesciences from $78.00 to $75.00 and set a "hold" rating for the company in a research note on Friday. Canaccord Genuity Group raised their price target on shares of Edwards Lifesciences from $68.00 to $71.00 and gave the stock a "hold" rating in a report on Thursday, February 13th. Bank of America upgraded shares of Edwards Lifesciences from a "neutral" rating to a "buy" rating and lifted their price objective for the company from $82.00 to $90.00 in a research note on Monday, December 16th. Stifel Nicolaus raised Edwards Lifesciences from a "hold" rating to a "buy" rating and raised their target price for the stock from $75.00 to $90.00 in a report on Thursday, January 30th. Finally, Royal Bank of Canada reaffirmed an "outperform" rating and issued a $85.00 price objective on shares of Edwards Lifesciences in a report on Wednesday, February 12th. One investment analyst has rated the stock with a sell rating, fourteen have given a hold rating and ten have issued a buy rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Hold" and an average price target of $78.55.

Insider Buying and Selling at Edwards Lifesciences

In other news, VP Donald E. Bobo, Jr. sold 6,500 shares of the firm's stock in a transaction that occurred on Thursday, February 13th. The shares were sold at an average price of $75.75, for a total transaction of $492,375.00. Following the completion of the transaction, the vice president now directly owns 46,936 shares of the company's stock, valued at $3,555,402. This trade represents a 12.16 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, VP Daniel J. Lippis sold 400 shares of the business's stock in a transaction on Monday, March 10th. The stock was sold at an average price of $69.48, for a total value of $27,792.00. Following the completion of the transaction, the vice president now directly owns 22,588 shares of the company's stock, valued at approximately $1,569,414.24. This trade represents a 1.74 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 62,853 shares of company stock valued at $4,534,247. 1.29% of the stock is owned by corporate insiders.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.